BOLD

Boundless Bio, Inc. (BOLD) - Q1 2026 10-Q Summary

Business Context and Reporting Period

Boundless Bio, Inc. is a clinical-stage oncology company developing extrachromosomal DNA (ecDNA)-directed therapeutic candidates (ecDTx). The company focuses on its lead candidate, BBI-940, a kinesin degrader currently in Phase 1 clinical trials (KOMODO-1) for ER+/HER2- and TNBC-LAR breast cancer. This report covers the quarterly period ended March 31, 2026. The company has no approved products and has not generated any revenue to date.

Key Financial Metrics

Note: All figures in millions unless otherwise noted. The company reported no debt obligations other than lease liabilities.

Material Changes vs. Prior Period

• Expense Reduction: Total operating expenses decreased by $2.9 million (16.5%) year-over-year, driven by a $2.4 million reduction in R&D and a $0.5 million reduction in G&A. This was primarily due to workforce reductions and the winding down of the POTENTIATE (BBI-355) and STARMAP (BBI-825) clinical trials.
• Portfolio Prioritization: R&D spending shifted focus to BBI-940, with direct program costs for BBI-940 increasing by $3.1 million to $3.9 million, while costs for discontinued programs dropped significantly.
• Interest Income: Interest income decreased by $0.7 million to $0.9 million due to a lower investable asset base and declining market yields.
• Investment Portfolio: Short-term investments decreased from $89.7 million to $75.4 million as the company utilized maturities to fund operations.

Outlook, Management Commentary, and Risks

• Cash Runway: Management believes existing cash and investments ($92.8 million) are sufficient to fund operations into the second half of 2028, assuming current operating plans hold.
• Facility Restructuring (Subsequent Event): In April 2026, the company terminated its long-term San Diego lease (effective May 31, 2026) and entered a new, smaller lease in La Jolla. This involved a $10.0 million termination payment and the forfeiture of a $0.5 million security deposit. The company expects to recognize approximately $2.4 million in charges in Q2 2026 related to this transition.
• Capital Needs: The company expects to incur significant losses for the foreseeable future and will require substantial additional capital to complete clinical development and potential commercialization. Future funding may come from equity offerings, debt, or collaborations.
• Risks: Key risks include the failure of BBI-940 to demonstrate efficacy or safety in clinical trials, the inability to raise additional capital, and the high uncertainty associated with the novel ecDNA therapeutic approach.

Investor Verification Checklist

• Lease Termination Impact: Verify the exact timing and accounting treatment of the $10.5 million cash outflow and the expected $2.4 million Q2 2026 charge related to the facility move.
• Cash Burn Rate: Monitor the quarterly cash burn rate to confirm the "second half of 2028" runway estimate remains valid given the recent lease termination costs.
• BBI-940 Trial Progress: Track enrollment and initial safety/efficacy data readouts from the KOMODO-1 Phase 1 trial, which is the company's sole remaining clinical asset.
• Capital Raising: Review the status of the "at-the-market" (ATM) offering agreement; no shares have been sold under this agreement as of March 31, 2026.
• Stock-Based Compensation: Note that $9.5 million of unrecognized stock-based compensation remains, which will impact future operating expenses.